Gynecologic Malignancies in the Elderly

  • Peter E. Schwartz
  • Thomas L. Rutherford


Pelvic reproductive organ cancers include those that arise in the vulva, vagina, cervix, uterus, fallopian tubes, and ovaries. In the United States uterine cancer is the fourth most common cancer women develop,1 ovarian cancer is the fifth most common, and cervical cancer is the ninth most common. Cervical cancer is the second most common cancer in women worldwide.2 The reason for the disparity between the worldwide and American figures is believed to be the lack of adequate Papanicolaou (Pap) smear screening in many underdeveloped countries of the world. Data from the Connecticut Tumor Registry, the oldest population-based registry in the United States, reveals that 20% of female pelvic reproductive organ cancers in Connecticut occur in women age 70 years or more (Table 59.1).3 Thus cancers of the pelvic reproductive tract can and do occur in elderly women, and their management must be adjusted for the individual’s physical and mental status.


Cervical Cancer Human Papilloma Virus Fallopian Tube Cytoreductive Surgery Human Papilloma Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parker SL, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Boffetta P, Parkin DM. Cancer in developing countries. CA Cancer J Clin 1994;44:81–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Heston JF, Kelly JAB, Meigs JW, Flannery JT. Forty-five years of cancer incidence in Connecticut: 1935–1979. Natl Cancer Inst Monogr 1986;70:359–398.Google Scholar
  4. 4.
    Van Beurden M, ten Kate FJ, Smits HL, et al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papilloma virus. Cancer 1995;75: 2879–2884.PubMedCrossRefGoogle Scholar
  5. 5.
    Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papilloma virus DNA in vulvar carcinoma. Obstet Gynecol 1995;85: 709–715.PubMedCrossRefGoogle Scholar
  6. 6.
    Pettersson F Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991;36(suppl): 278–285.Google Scholar
  7. 7.
    Fishman DA, Chambers SK, Kohorn EI, Chambers JT. Extramammary Paget’s disease of the vulva. Gynecol Oncol 1995; 56:266–270.PubMedCrossRefGoogle Scholar
  8. 8.
    Edwards CL, Tortolero-Luna G, Linares AC, et al. Vulvar intraepithelial neoplasia and vulvar cancer. Obstet Gynecol Clin North Am 1996;23:295–324.PubMedGoogle Scholar
  9. 9.
    International Society for the Study of Vulvar Disease: New nomenclature for vulvar disease. Obstet Gynecol 1976;47: 122.Google Scholar
  10. 10.
    Homesley HD. Management of vulvar cancer. Cancer 1995;76(suppl):2159–2170.PubMedCrossRefGoogle Scholar
  11. 11.
    Stehman FB, Bundy BW, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992;79:490–197.PubMedGoogle Scholar
  12. 12.
    Morris JM. A formula for selective lymphadenectomy: its application to cancer of the vulva. Obstet Gynecol 1977;50: 152–158.PubMedGoogle Scholar
  13. 13.
    Hoffman MS, Mark JE, Cavanagh D. A management scheme for postoperative groin lymphocysts. Gynecol Oncol 1995; 56:262–265.PubMedCrossRefGoogle Scholar
  14. 14.
    Levenback C, Burke TW, Gershenson DM, Morris M, Malpica A, Ross ML Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994;84:163–167.PubMedGoogle Scholar
  15. 15.
    Boronow RC, Hickman BT, Reagan MT, Steadham RE. Combined therapy as an alternative to exenteration for locally advanced vulvovaginal cancer. II. Results, complications and dosimetric and surgical considerations. Am J Clin Oncol 1987;10:171–181.PubMedCrossRefGoogle Scholar
  16. 16.
    Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulva carcinoma. Gynecol Oncol 1996;61:321–327.PubMedCrossRefGoogle Scholar
  17. 17.
    Cunningham MJ, Goyer RP, Gibbons SK, Kredentser SC, Malfetano JH, Keys H. Primary radiation, cisplatin and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997;66:258–261.PubMedCrossRefGoogle Scholar
  18. 18.
    Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986;68: 733–740.PubMedGoogle Scholar
  19. 19.
    Burger MPM, Hollema H, Emanuels AG, Kraws M, Pras E, Bouma J. The importance of the groin node status for the survival of T1 and T2 vulvar carcinoma patients. Gynecol Oncol 1995;57:377–334.CrossRefGoogle Scholar
  20. 20.
    Sugase M, Matsukura T. Distinct manifestations of human papilloma viruses in the vagina. Int J Cancer 1997;72:412–415.PubMedCrossRefGoogle Scholar
  21. 21.
    Minucci D, Cinel A, Insacco E, Oselladore M. Epidemiological aspects of vaginal intraepithelial neoplasia (VAIN). Clin Exp Obstet Gynecol 1995;22:36–42.PubMedGoogle Scholar
  22. 22.
    Pettersson F. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991;36(suppl): 302–308.Google Scholar
  23. 23.
    Stock RG, Chen AS, Seski J. A 30 year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 1995;56:45–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1996;35:891–905.PubMedCrossRefGoogle Scholar
  25. 25.
    Janerich DT, Hajimichael O, Schwartz PE, et al. Cervical cancer, Connecticut. Am J Public Health 1995;85:791–794.PubMedCrossRefGoogle Scholar
  26. 26.
    Pettersson F. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991;36(suppl): 27–43.Google Scholar
  27. 27.
    Brinton LA, Fraumeni JF. Epidemiology of uterine cervical carcinoma. J Chronic Dis 1986;31:1051.CrossRefGoogle Scholar
  28. 28.
    Holly EA. Cervical intraepithelial neoplasia, cervical cancer and HPV. Annu Rev Public Health 1996;17:69–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974;44:265–272.PubMedGoogle Scholar
  30. 30.
    Perez CA. Radiation therapy in the management of cancer of the cervix. Oncology 1993;7:89–96.PubMedGoogle Scholar
  31. 31.
    Keys H, Gibbons SK. Optimal management of locally advanced cervical carcinoma. J Natl Cancer Inst Monogr 1996;21:89–92.PubMedGoogle Scholar
  32. 32.
    Kapp DS, Fischer D, Gutierrez E, Kohorn EI, Schwartz PE. Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariate analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 1983;9:445–455.PubMedCrossRefGoogle Scholar
  33. 33.
    Magrina HF, Stanhope CR, Weaver AL. Pelvic exenterations: supralevator, infralevator and with vulvectomy. Gynecol Oncol 1997;64:130–135.PubMedCrossRefGoogle Scholar
  34. 34.
    Penalven MA, Barreau G, Sevin BU, Averette HE. Surgery for the treatment of locally recurrent disease. J Natl Cancer Inst Mongr 1996;21:117–122.Google Scholar
  35. 35.
    Vergote IB. Exenterative surgery. Curr Opin Obstet Gynecol 1997;9:25–28.PubMedCrossRefGoogle Scholar
  36. 36.
    Burke TW, Weiser EB, Hoskins WJ, Heller PB, Nash JD, Park RC. End colostomy using the end-to-end anastomosis instrument. Obstet Gynecol 1987;156–159.Google Scholar
  37. 37.
    Rose PG. Endometrial carcinoma. N Engl J Med 1997;335: 640–649.CrossRefGoogle Scholar
  38. 38.
    Hannigan EV, Gomez LG. Uterine leiomyosarcoma. Am J Obstet Gynecol 1979;134:557–564.PubMedGoogle Scholar
  39. 39.
    Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Malignant uterine smooth muscle tumors: role of etoposide, cisplatin and doxorubicin (EPA) chemotherapy. J Surg Oncol 1996;63:145–147.PubMedCrossRefGoogle Scholar
  40. 40.
    Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumors when adjusting for known prognostic factors: the results of a retrospective study of 432 cases of uterine sarcoma. Br J Obstet Gynaecol 1992;99:590–594.PubMedCrossRefGoogle Scholar
  41. 41.
    Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol 1995;56:370–375.PubMedCrossRefGoogle Scholar
  42. 42.
    Katz L, Merino MJ, Sakamoto J, Schwartz PE. Endometrial stromal sarcoma: estrogen and progestin receptor levels and their significance in hormone treatment. Gynecol Oncol 1987;26:87–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Kurman RK, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403–412.PubMedCrossRefGoogle Scholar
  44. 44.
    Pettersson F. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991;36(suppl): 132–155.Google Scholar
  45. 45.
    Morrow CP, Bundy BW, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcomes in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:50–65.CrossRefGoogle Scholar
  46. 46.
    Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 1996;61:189–196.PubMedCrossRefGoogle Scholar
  47. 47.
    Cormio G, Maneo A, Gabriele A, Rota SM, Lisson A, Zanetta G. Primary carcinoma of the fallopian tube: a retrospective analysis of 47 patients. Ann Oncol 1996;7:271–275.PubMedCrossRefGoogle Scholar
  48. 48.
    Baekelandt M, Kockx M, Wesling F, Gerris J. Primary adenocarcinoma of the fallopian tube: review of the literature. Int J Gynecol Cancer 1993;3:65–71.PubMedCrossRefGoogle Scholar
  49. 49.
    Brown MD, Kohorn EI, Kapp DS, Schwartz PE, Merino M. Fallopian tube carcinoma. Int J Radiat Oncol Biol Phys 1985;11:583–590.PubMedCrossRefGoogle Scholar
  50. 50.
    Rosen AC, Klein M, Rosen HR, et al. Preoperative and postoperative CA 125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet 1994;255:65–681.PubMedCrossRefGoogle Scholar
  51. 51.
    Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550–1559.PubMedCrossRefGoogle Scholar
  52. 52.
    Pettersson F Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991;36(suppl): 238–257.Google Scholar
  53. 53.
    Fishman DA, Schwartz PE. Current approaches to the diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol 1994;6:98–104.PubMedCrossRefGoogle Scholar
  54. 54.
    Price FV, Schwartz PE. Management of ovarian stromal tumors. In: Rubin SC, Sutton GP (eds) Ovarian Cancer. New York: McGraw Hill, 1993:405–423.Google Scholar
  55. 55.
    Cass I, Chambers JT, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE. Combination chemotherapy with etoposide, cisplatin and doxorubicin in mixed mullerian tumors of the adnexa. Gynecol Oncol 1996;61:309–314.PubMedCrossRefGoogle Scholar
  56. 56.
    Schwartz PE. Surgical management of ovarian cancer. Arch Surg 1981;116:99–106.PubMedCrossRefGoogle Scholar
  57. 57.
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–166.PubMedCrossRefGoogle Scholar
  58. 58.
    Schwartz PE. Neoadjuvant chemotherapy for advanced ovarian cancer. J Gynecol Techniques 1995;1:175–180.Google Scholar
  59. 59.
    Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166–172.PubMedGoogle Scholar
  60. 60.
    Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival (Gynecol Oncol 1999;72:93–99).PubMedGoogle Scholar
  61. 61.
    Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993;11:434–439.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Peter E. Schwartz
  • Thomas L. Rutherford

There are no affiliations available

Personalised recommendations